Prospective, Multi-institutional Study Shows CyberKnife SBRT Treatment Results in Low PSA Nadir for Low- and Intermediate-risk Prostate Cancer Patients SUNNYVALE, Calif. , Feb. 16, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective, Phase II, 17-center
Latest research published in The Lancet Oncology : suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical CyberKnife platform
SUNNYVALE, Calif. , Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announces that The Lancet Oncology , a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances in Comparative
SUNNYVALE, Calif. , March 28, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the appointment of Emad Rizk , M.D. to the company's Board of Directors, effective March 15, 2013 . Dr. Rizk is a renowned healthcare industry expert who brings more than 25 years of experience
SUNNYVALE, Calif. , Sept. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Seth Blacksburg, M.D., MBA has joined the company as vice president, chief medical officer for the Americas ( North and South America ) region. Dr.
Installation at Korea Cancer Care Hospital Marks First Hospital in Asia with Two CyberKnife Systems in Use SUNNYVALE, Calif., Oct 27, 2010 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the Korea Cancer Care
Physician Usage and Patient Demand Grow Dramatically SUNNYVALE, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that emerging clinical data continues to support CyberKnife radiosurgery for the treatment of
New Clinical Trial Evaluates Use of Online-Adaptive Stereotactic Body Radiation Therapy Approach in the Treatment of Oligometastases SUNNYVALE, Calif. and ROTTERDAM, Netherlands, March 27, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Erasmus MC, the largest university medical
SUNNYVALE, Calif. , Oct. 19, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy® System by University Hospital of Tours (CHU).
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.